OpenClinica, LLC, announces the availability of the latest version of its popular open source clinical trials software. The OpenClinica v3.1.3 release contains over 100 fixes and enhancements, including:
These, and many other, advancements are the result of efforts by OpenClinica, LLC and members of the OpenClinica community. “OpenClinica community contributors have helped fuel a lot of the progress reflected in this release,” said Cal Collins, OpenClinica’s CEO. “This release is evidence that a strong open source community can drive the software to a higher quality standard.”
OpenClinica 3.1.3 Community Edition is freely available for download on the OpenClinica community website.
The company also announces that version 3.1.3 of its commercially backed OpenClinica Enterprise Edition is also now available. OpenClinica Enterprise is provided as fully validated, enhanced, and supported implementation of the open source technology, ideal for mission critical environments. This latest rendition of the OpenClinica Enterprise Edition also leverages Akamai’s global content delivery network (CDN), further accelerating the application’s performance.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.